News

Earlier this year, Isis signed a license agreement with Bayer HealthCare for the development and commercialization of ISIS-FXIRx to prevent clotting disorders. Upon completion of ongoing activities at

Pexidartinib is an investigational novel, oral small molecule that selectively inhibits a primary growth driver of abnormal cells in the synovium that causes TGCT called colony stimulating factor-1

It is the fifth indication for Eylea, which is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. Bayer is co-developing Eylea with

These findings are a step forward in the development of targeted therapies for hard-to-treat cancers. The American Cancer Society estimates that in 2015, about 21,290 new cases of

FDA’s Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with Fast

TTIL will support a Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in

Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai. The facility will provide analytical and stability services, including analytical

Pfizer’s current PCMM prototype is an autonomous and transportable pod that may be quickly shipped from location to location and readily brought online to create a fully functional

Vidaza is indicated to treat adult patients aged 65 years or older with AML who are not eligible for haematopoietic stem cell transplantation (HSCT). The commission updated Vidaza